### Specialist Working Group for Haematology

#### Proposed changes to the *Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition*

| **ITEM** | **CRITERIA FOR THE CLINICAL USE OF INTRAVENOUS IMMUNOGLOBULIN IN AUSTRALIA, SECOND EDITION (CRITERIA)** | **PROPOSED REVISIONS TO THE CRITERIA**  | **SWG RATIONALE FOR PROPOSED CHANGE****(A) Administrative)****(B) Progressive** **(C) Programmed** |
| --- | --- | --- | --- |
| **Condition Name** | **Neonatal haemochromatosis (NH)** | **Neonatal haemochromatosis (NH)** |  |
| **Specialty** | Haematology  | Haematology |  |
| **Chapter** | 5 | 5 |  |
| **Specific Conditions** |  |  |  |
| **Level of Evidence** | Evidence of probable benefit ([Category 2a](http://www.blood.gov.au/pubs/ivig/development-and-maintenance-of-the-criteria.html#el-2a)). | Evidence of probable benefit ([Category 2a](http://www.blood.gov.au/pubs/ivig/development-and-maintenance-of-the-criteria.html#el-2a)). |  |
| **Justification for Evidence Category** | A trial compared the impact of IVIg on pregnancy outcome of women whose most recent pregnancy had resulted in NH with historical controls (randomly selected previously affected pregnancies). All 15 pregnancies resulted in live births. NH was diagnosed in 11 but responded to medical treatment. By contrast, there were 2 successful outcomes in controls (Biotext 2004). | A trial compared the impact of intravenous immunoglobulin (IVIg) on pregnancy outcome of women whose most recent pregnancy had resulted in NH with historical controls (randomly selected previously affected pregnancies). All 15 pregnancies resulted in live births. NH was diagnosed in 11 but responded to medical treatment. By contrast, there were two successful outcomes in controls (Biotext 2004). Rand et al (2009) describes successful treatment of NH in neonates using exchange transfusion and IVIg.  | Addition of evidence with successful use of IVIg together with exchange transfusion. (A) |
| **Description and Diagnostic Criteria** | NH manifests in the foetus and newborn and is characterised by abnormal accumulation of iron in the liver and extra-hepatic tissues. Affected neonates present with fulminant liver failure, usually in the context of a history of prematurity, intrauterine growth retardation and oligohydramnios. NH differs from most other causes of neonatal liver disease, other than congenital infections, in that the condition begins in utero and fulminant liver disease is manifested in the first few days of life. The aetiology and pathogenesis remains uncertain. The NH phenotype may be the outcome of numerous disease processes. There is also evidence, however, that NH is an alloimmune disorder. First, there is an approximate 80% likelihood of NH once a woman has an affected baby. Second, mothers can have affected babies with different fathers. It has not been described that fathers can have affected half-siblings with different mothers.**Symptoms and signs**Affected neonates present with signs of liver failure, including extreme cholestasis, hypoalbuminaemia, coagulopathy, ascites and hypoglycaemia.Diagnosis of neonatal haemochromatosis is made after other causes of neonatal liver failure have been ruled out.In addition to extensive iron deposition (siderosis), liver biopsy would show cirrhosis with diffuse fibrosis, bile duct proliferation, and giant cells. Siderosis is also present in other tissues and viscera (e.g. epithelial tissues and the heart) but not in reticuloendothelial cells.**Occurrence**NH is a rare disease but the rate of recurrence after the index case in a sibship is up to 80%.**Prognosis**About 20% survival with medical treatment. | **Ne** NH manifests in the foetus and newborn, and is characterised by abnormal accumulation of iron in the liver and extra-hepatic tissues. Affected neonates present with fulminant liver failure, usually in the context of a history of prematurity, intrauterine growth retardation and oligohydramnios. NH differs from most other causes of neonatal liver disease, other than congenital infections, in that the condition begins in utero and fulminant liver disease is manifested in the first few days of life. The aetiology and pathogenesis remains uncertain. The NH phenotype may be the outcome of numerous disease processes. There is also evidence, however, that NH is an alloimmune disorder. First, there is an approximate 80% likelihood of NH once a woman has an affected baby. Second, mothers can have affected babies with different fathers. It has not been described that fathers can have affected half-siblings with different mothers.**Symptoms and signs**Affected neonates present with signs of liver failure, including extreme cholestasis, hypoalbuminaemia, coagulopathy, ascites and hypoglycaemia.Diagnosis of neonatal haemochromatosis is made after other causes of neonatal liver failure have been ruled out.In addition to extensive iron deposition (siderosis), liver biopsy would show cirrhosis with diffuse fibrosis, bile duct proliferation, and giant cells. Siderosis is also present in other tissues and viscera (e.g. epithelial tissues and the heart), but not in reticuloendothelial cells.**Occurrence**NH is a rare disease but the rate of recurrence after the index case in a sibship is up to 80%.**Prognosis**About 20% survival with medical treatment.**haemochromatosis (NH)** |  |
| **Diagnosis is required** |   | No | Which Speciality |  |  |
| **Diagnosis must be verified** |   | No | Which Specialty |  |  |
| **Exclusion Criteria** |  |  |  |
| **Indication for use** | Pregnant women who have had a previous pregnancy affected by neonatal haemochromatosis. | **Pregnant women who have had a previous pregnancy affected by neonatal haemochromatosis.****Neonate with neonatal haemochromatosis.** | Addition of indication of treatment in neonate with IVIg and exchange transfusion. (A) |
| **Qualifying Criteria** | Women who are pregnant or attempting to conceive and their most recent pregnancy ended in delivery of a foetus shown to have had NH. | **Pregnant women who have had a previous pregnancy affected by NH.**Pregnant woman or woman attempting to conceive with a previous pregnancy ending in delivery of a fetus shown to have had NH.**Neonate with NH.**A diagnosis of NH confirmed in a neonate by exclusion of other causes of neonatal liver failure and findings of high ferritin in liver biopsy, and MRI demonstration of iron overload. | Qualifying Criteria aligned with current criteria however, SWG recommends wording in the current version is too restrictive to limit to the ‘most recent’ pregnancy (Qualifying criteria) and the wording of the original indication should be used (previous pregnancy). (A)Qualifying criteria and evidence items defined to confirm Neonatal NH diagnosis. (A) |
| **Review Criteria** | * Occurrence of NH, or evidence of liver disease (serum ferritin and a-fetoprotein levels, coagulopathy) in the offspring of women who have previously given birth to an NH-affected neonate.
* Requirement for liver transplantation in these neonates.
* Survival and development of infants following maternal IVIg therapy during pregnancy.
 | **Pregnant women who have had a previous pregnancy affected by NH.****Review Is Required** No**Continuing Treatment is permitted** No**Continuing authorisation request is required** N/A**Maximum Authorised Treatment Period (Initial)** 5 months**Maximum Authorised Treatment Period (Continuing Reqs)** N/A **Who must undertake review** Treating Specialist**If review NOT required** **maximum length of authorisation** 5 months**Consider cessation** Yes**Consider Cessation Timeframe** 5 monthsReview criteria for assessing the effectiveness of IVIg use: The occurrence of NH, or evidence of liver disease in the offspring of women who have previously given birth to an NH-affected neonate. * Pregnancy resulted in live birth.
* Evidence of liver disease in the neonate.
* Requirement for liver transplantation in the neonate.

**Neonate with NH.****Review Is not required for this indication.****Consider Cessation Timeframe**  5 monthsReview criteria for assessing the effectiveness of IVIg use: * Evidence of liver disease in the neonate (T/F)
* Requirement for liver transplantation in the neonate
 | While the maximum term would be 42 weeks for a normal pregnancy, these pregnancies are likely to be induced earlier. SWG confirmed that the maximum time of 5 months treatment (i.e. treat from 18 until 38 weeks pregnant) was sufficient. (A)Outcome data has been defined. (A) |
| **Dose** | 1 g/kg body weight weekly from the 18th week until the end of gestation.**Refer to the current product information sheet for further information.****The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.** | **Pregnant women who have had a previous pregnancy affected by NH.****Maintenance** - 1 g/kg body weight (to a maximum of 100 kg) weekly from the 18th week until the end of gestation.**Min Dose per kg**  1 **Max Dose per kg** 1**Administer in a divided dose** NoCommence week 18 of pregnancy and finish at gestation.**Neonate with NH.** Up to 2 g/kg following exchange transfusion in the first 7 days and then 1 g/kg weekly, as required.The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.**Refer to the current product information sheet for further information.** | Dosing in pregnant women consistent with current version with the addition of defining a maximum maternal weight of 100Kg given the high incidence of obesity in the pregnant population. (B)Dosing for neonates consistent with literature. (B)  |

|  |
| --- |
| **POTENTIAL OPERATIONAL IMPACT** |
| It is unlikely that there will be any operational impact for this condition from transitioning to the revised Criteria. Where prescribers may have been unaware of the benefits of new evidence, improved clinical outcome might be expected. |
| **POTENTIAL IMPACT ON DEMAND** |
| **2013-14 Patient Numbers****2013-14 Usage** |  **6 patients****<1% total use** | Given the very low patient numbers, no impact is anticipated on demand. |   |
| **POTENTIAL IMPACT ON COST** |
| **Current cost** |  | **Anticipated reduction in cost, if any****Marginal** = borderline or unchanged from current cost**Minor** = decrease by $500K - $1.99M from current cost**Major** = decrease $2M+ from current cost | **Marginal** |
| **BIBLIOGRAPHY** |
| Flynn, DM, Mohan, N, McKiernan, P, et al 2003, ‚Progress in treatment and outcome for children with neonatal haemochromatosis’, *Archives of Disease in Childhood – Foetal Neonatal Edition*, vol. 88, no. 2, pp. F124–7.Knisely, AS, Mieli-Vergani, G & Whitington, PF 2003, ‘Neonatal haemochromatosis’, *Gastroenterology Clinics of North America*, vol. 32, no. 3, pp. 877–89, vi–vii.Rand, EB, Karpen, SJ, Kelly, S, et al 2009, ‘Treatment of hemochromatosis with exchange transfusion and intravenous immunoglobulin’, *Journal of Pediatrics,* vol. 155, no. 4, pp. 566–71. Rodriguez, F, Kallas, M, Nash, R, et al 2005, ‘Neonatal haemochromatosis – medical treatment vs. transplantation: the King’s experience’, *Liver Transplantation*, vol. 11, no. 11, pp. 1417–24.Schneider, BL 1996, ‘Neonatal liver failure’, *Current Opinion in Paediatrics*, vol. 8, pp. 495–501.Whittington, PF & Hibbard, JU 2004, ‘High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis’, *Lancet*, vol. 364, pp. 1690–8.Whittington, PF, Kelly, S & Ekong, UD 2005, ‘Neonatal haemochromatosis: foetal liver disease leading to liver failure in the foetus and newborn’, *Paediatric Transplantation*, vol. 9, pp. 640–5. |
| **END OF DOCUMENT** |